What can a patient do if already on the max dose of Ozempic injections but plateaued in weight loss and A1C?

The short version: at max-dose Ozempic with a plateau, the evidence supports switching to tirzepatide (Mounjaro/Zepbound) or adding a non-GLP-1 drug, but long-term data on either strategy is thin.

The strongest option is tirzepatide, a dual GIP/GLP-1 agonist. A 2025 systematic review found tirzepatide produced weight loss of 5.4 to 12.9 kg and HbA1c reductions of 1.87% to 3.02% across the SURPASS trials [3]. In the SURMOUNT-1 trial, adults without diabetes lost 16.5% to 22.4% of body weight over 72 weeks [3]. These numbers come from manufacturer-funded trials, and no head-to-head study directly compares tirzepatide to continuing max-dose semaglutide in plateaued patients.

A 2026 retrospective study found that longer GLP-1 therapy duration did not predict durable weight loss after stopping. In fact, longer tirzepatide use was associated with more weight regain after cessation [1]. This matters because it suggests the plateau is not a timing problem—staying on the same drug longer may not help.

For A1C specifically, oral semaglutide (Rybelsus) is an option. The PIONEER program showed oral semaglutide 14 mg lowered HbA1c by about 1.1% and produced weight loss of about 2.3 kg versus placebo [2]. But oral semaglutide has only about 2.5% bioavailability and causes more nausea [2]. No trial directly compared oral semaglutide to continuing injectable semaglutide at max dose.

Non-drug options exist but are poorly studied in this specific scenario. Sleeve gastrectomy with transit bipartition produced dramatic results—BMI dropped from 42 to 24.8 and HbA1c from 9.1% to normal in one small 2018 study [4]. That is a major surgery with its own risks.

My call: switching to tirzepatide is the most evidence-backed next step, but the evidence base is thin for plateaued patients specifically. Confidence: low, because no trial has studied this exact scenario.